News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,177 Results
Type
Article (14926)
Company Profile (299)
Press Release (266946)
Multimedia
Podcasts (79)
Webinars (11)
Section
Business (79870)
Career Advice (163)
Deals (13342)
Drug Delivery (39)
Drug Development (50709)
Employer Resources (31)
FDA (5843)
Job Trends (5171)
News (145129)
Policy (10074)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (21)
Adcomms (14)
Allergies (86)
Alliances (21764)
ALS (127)
Alzheimer's disease (1042)
Antibody-drug conjugate (ADC) (248)
Approvals (6042)
Artificial intelligence (271)
Autoimmune disease (124)
Automation (9)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (103)
Biotechnology (230)
Bladder cancer (102)
Brain cancer (47)
Breast cancer (349)
Cancer (3188)
Cardiovascular disease (243)
Career advice (148)
Career pathing (8)
CAR-T (225)
CDC (5)
Cell therapy (580)
Cervical cancer (14)
Clinical research (43756)
Collaboration (1178)
Company closure (2)
Compensation (610)
Complete response letters (43)
COVID-19 (1103)
CRISPR (91)
C-suite (578)
Cystic fibrosis (112)
Data (4398)
Denatured (16)
Depression (96)
Diabetes (257)
Diagnostics (1387)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (198)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (220)
Earnings (31718)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51775)
Executive appointments (631)
FDA (7625)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (999)
Gene editing (188)
Generative AI (22)
Gene therapy (498)
GLP-1 (509)
Government (1152)
Grass and pollen (3)
Guidances (166)
Healthcare (6619)
HIV (19)
Huntington's disease (44)
IgA nephropathy (75)
Immunology and inflammation (197)
Immuno-oncology (44)
Indications (76)
Infectious disease (1216)
Inflammatory bowel disease (160)
Inflation Reduction Act (10)
Influenza (43)
Intellectual property (171)
Interviews (18)
IPO (7347)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (24)
Layoffs (244)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (429)
Lymphoma (254)
Machine learning (24)
Management (7)
Manufacturing (383)
MASH (133)
Medical device (2677)
Medtech (2686)
Mergers & acquisitions (6630)
Metabolic disorders (738)
Multiple sclerosis (107)
NASH (13)
Neurodegenerative disease (239)
Neuropsychiatric disorders (70)
Neuroscience (1987)
Neurotech (1)
NextGen: Class of 2026 (2038)
Non-profit (867)
Now hiring (31)
Obesity (337)
Opinion (126)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (167)
Parkinson's disease (235)
Partnered (12)
Patents (313)
Patient recruitment (350)
Peanut (44)
People (26732)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15503)
Phase 2 (20332)
Phase 3 (12838)
Pipeline (3444)
Policy (92)
Postmarket research (853)
Preclinical (6546)
Press Release (30)
Prostate cancer (148)
Psychedelics (50)
Radiopharmaceuticals (242)
Rare diseases (668)
Real estate (1448)
Recruiting (12)
Regulatory (9956)
Reports (20)
Research institute (975)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (18)
Schizophrenia (125)
Series A (186)
Series B (141)
Service/supplier (1)
Sickle cell disease (79)
Special edition (19)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2009)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (345)
Venture capital (70)
Weight loss (174)
Women's health (27)
Worklife (2)
Date
Today (50)
Last 7 days (285)
Last 30 days (1258)
Last 365 days (17811)
2026 (2198)
2025 (18109)
2024 (20548)
2023 (22416)
2022 (26831)
2021 (27807)
2020 (23356)
2019 (16228)
2018 (11745)
2017 (13746)
2016 (11842)
2015 (14350)
2014 (10393)
2013 (7485)
2012 (7532)
2011 (7621)
2010 (7431)
Location
Africa (154)
Alabama (66)
Alaska (2)
Arizona (72)
Arkansas (6)
Asia (18286)
Australia (3117)
California (7199)
Canada (1874)
China (787)
Colorado (250)
Connecticut (259)
Delaware (239)
Europe (39257)
Florida (920)
Georgia (210)
Hawaii (2)
Idaho (17)
Illinois (400)
India (36)
Indiana (164)
Iowa (8)
Japan (231)
Kansas (81)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (748)
Massachusetts (5665)
Michigan (110)
Minnesota (252)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1670)
New Mexico (13)
New York (1789)
North Carolina (845)
North Dakota (6)
Northern California (3541)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1300)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2860)
Tennessee (41)
Texas (927)
United States (23721)
Utah (98)
Virginia (140)
Washington D.C. (37)
Washington State (595)
West Virginia (1)
Wisconsin (47)
282,177 Results for "fulcrum therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2026
February 9, 2026
·
1 min read
Press Releases
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
·
1 min read
Press Releases
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 17, 2026
·
3 min read
Press Releases
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 9, 2026
January 12, 2026
·
1 min read
Press Releases
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
December 9, 2025
·
5 min read
Press Releases
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
·
5 min read
Press Releases
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
December 8, 2025
·
1 min read
Press Releases
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
October 29, 2025
·
9 min read
Press Releases
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 7, 2025
November 10, 2025
·
2 min read
Press Releases
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
December 3, 2025
·
5 min read
1 of 28,218
Next
